Medicines for an aging Population

Presentations from the EMA workshop on ensuring safe and effective medicines for an ageing population.

Presentation 9 was on "How to get better data on medicines post-licensing", but was too big to upload! All presentations are also available from the European Medicines Agency.

1. Programme - Agenda Ensuring safe and effective medicines for an ageing population.pdf

2. Presentation - European Medicines Agency geriatric medicines strategy.pdf

3. Presentation - Healthy ageing and medicines - the patients' perspective of ageing.pdf

4. Presentation - The industry's views on geriatric medicines.pdf

5. Presentation - International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E7 requirements.pdf

6. Presentation - Elderly patients and clinical trials European Medicines Agency notes for guidance.pdf7. Presentation - Can pharmacokinetics and modelling help.pdf

7. Presentation - Can pharmacokinetics and modelling help.pdf

8. Presentation - Modelling and simulation to support evaluation of safety and efficacy of drugs in older patients.pdf

10. Presentation - Endpoints and their relevance to older people cancer and palliative care and the work of the European Organization for Research and Treatment of Cancer.pdf

11. Presentation - Endpoints and indications for the older population.pdf

12. Presentation - Frailty Challenges and possible solutions.pdf

13. Presentation - The cluster medicine approach.pdf14. Presentation - The industry's views on 'older' old patients.pdf

14. Presentation - The industry's views on 'older' old patients.pdf

15. Presentation - Increasing enrolment in clinical trials and the Increasing the Participation of the Elderly In Clinical Trials (PREDICT) study.pdf

16. Presentation - Efficacy and effectiveness models.pdf

17. Presentation - Proposal for guidance on medical research for and with older people in Europe.pdf

18. Presentation - Practical proposals on recruitment improvement Research and development approach and focus on possible bottleneck issues.pdf

19. Presentation - Medication errors and screening tool of older persons’ potentially inappropriate prescriptions (STOPP) screening tool (START) criteria.pdf

20. Presentation - Predictors of outcome and renal clearance.pdf

21. Presentation - Pharmacovigilance and the elderly Some proposals for improvement.pdf

22. Presentation - EudraVigilance and signal detection.pdf

23. Presentation - Industry perspective.pdf

24. Presentation - Pharmacovigilance in the elderly Conclusions.pdf

25. Presentation - Formulations, packaging and medication practice considerations.pdf

26. Presentation - Industry perspective on formulation and packaging considerations.pdf

27. Presentation - What do we need to consider to ensure medication adherence of older adults.pdf

28. Presentation - Providing information to the older population Understanding the needs of older people.pdf

29. Presentation - A national-competent-authority analysis of approval documents.pdf

30. Presentation - How can SmPC and European-public-assessment-report information contribute to the safe and effective use of medicines in the older population.pdf

31. Presentation - Package leaflet initiatives.pdf

32. Presentation - Providing information to the older population An industry perspective.pdf

33. Presentation - Conclusions.pdf